Article Search
닫기

Microbiology and Biotechnology Letters

보문(Article)

View PDF

Molecular and Cellular Microbiology (MCM)  |  Functional Genomics and Systems Biology

Microbiol. Biotechnol. Lett. 2022; 50(1): 157-163

https://doi.org/10.48022/mbl.2108.08004

Received: August 15, 2021; Revised: December 30, 2021; Accepted: January 4, 2022

The Antimicrobial Insect Peptide CopA3 Blocks Ethanol-Induced Liver Inflammation and Liver Cell Injury in Mice

Ho Kim*

Division of Life Science and Chemistry, College of Natural Science, Daejin University, Pocheon 11159, Republic of Korea

Correspondence to :
Ho Kim,       hokim@daejin.ac.kr

Alcoholic liver disease (ALD), which encompasses alcoholic steatosis, alcoholic hepatitis, and alcoholic cirrhosis, is a major cause of morbidity and mortality worldwide. Although the economic and health impacts of ALD are clear, few advances have been made in its prevention or treatment. We recently demonstrated that the insect-derived antimicrobial peptide CopA3 exerts anti-apoptotic and anti-inflammatory activities in various cell systems, including neuronal cells and colonic epithelial cells. Here, we tested whether CopA3 inhibits ethanol-induced liver injury in mice. Mice were intraperitoneally injected with ethanol only or ethanol plus CopA3 for 24 h and then liver injury and inflammatory responses were measured. Ethanol enhanced the production of proinflammatory cytokines, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, interferon (IFN)-γ, and IL-10. It also induced hepatocyte apoptosis and ballooning degeneration in hepatocytes. Notably, all these effects were eliminated or significantly reduced by CopA3 treatment. Collectively, our findings demonstrate that CopA3 ameliorates ethanol-induced liver cell damage and inflammation, suggesting the therapeutic potential of CopA3 for treating ethanol-induced liver injury.

Keywords: Antimicrobial peptide (CopA3), insect-derived peptide, ethanol-induced liver injury, inflammation, apoptosis, ballooning degeneration

Graphical Abstract


  1. Chacko KR, Reinus J. 2016. Spectrum of alcoholic liver disease. Clin. Liver Dis. 20: 419-427.
    Pubmed
  2. Farooq MO, Bataller R. 2016. Pathogenesis and management of alcoholic liver disease. Dig. Dis. 34: 347-355.
    Pubmed KoreaMed
  3. Lackner C, Tiniakos D. 2019. Fibrosis and alcohol-related liver disease. J. Hepatol. 70: 294-304.
    Pubmed
  4. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, et al. 2012. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J. Clin. Invest. 122: 3476-3489.
    Pubmed KoreaMed
  5. Neuman MG, French SW, French BA, Seitz HK, Cohen LB, Mueller S, et al. 2014. Alcoholic and non-alcoholic steatohepatitis. Exp. Mol. Pathol. 97: 492-510.
    Pubmed KoreaMed
  6. Navarro CDC, Figueira TR, Francisco A, Dal'Bo GA, Ronchi JA, Rovani JC, et al. 2017. Redox imbalance due to the loss of mitochondrial NAD(P)-transhydrogenase markedly aggravates high fat diet-induced fatty liver disease in mice. Free Radic. Biol. Med. 113: 190-202.
    Pubmed
  7. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, et al. 2003. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J. Hepatol. 38: 419-425.
  8. Gonzalez-Reimers E, Castellano-Higuera A, Aleman-Valls R, Alvarez-Arguelles H, de la Vega-Prieto MJ, Abreu-Gonzalez P, et al. 2009. Relation between body fat and liver fat accumulation and cytokine pattern in non-alcoholic patients with chronic HCV infection. Ann. Nutr. Metab. 55: 351-357.
    Pubmed
  9. Neuman MG, Benhamou JP, Malkiewicz IM, Akremi R, Shear NH, Asselah T, et al. 2001. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin. Biochem. 34: 173-182.
  10. Singal AK, Bashar H, Anand BS, Jampana SC, Singal V, Kuo YF. 2012. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. Hepatology 55: 1398-1405.
    Pubmed
  11. Wilkinson PK, Rheingold JL. 1981. Arterial-venous blood alcohol concentration gradients. J. Pharmacokinet. Biopharm. 9: 279-307.
    Pubmed
  12. Cederbaum AI. 2012. Alcohol metabolism. Clin Liver Dis 16: 667685.
    Pubmed KoreaMed
  13. Orrego H, Blake JE, Blendis LM, Medline A. 1987. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 92: 208-214.
  14. Shah ND, Ventura-Cots M, Abraldes JG, Alboraie M, Alfadhli A, Argemi J, et al. 2019. Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide. Clin. Gastroenterol. Hepatol. 17: 2320-2329.
    Pubmed KoreaMed
  15. Varma V, Webb K, Mirza DF. 2010. Liver transplantation for alcoholic liver disease. World J. Gastroenterol. 16: 4377-4393.
    Pubmed KoreaMed
  16. Kim SJ, Kim IW, Kwon YN, Yun EY, Hwang JS. 2012. Synthetic Coprisin analog peptide, D-CopA3 has antimicrobial activity and pro-apoptotic effects in human leukemia cells. J. Microbiol. Biotechnol. 22: 264-269.
    Pubmed
  17. Kim DH, Hwang JS, Lee IH, Nam ST, Hong J, Zhang P, et al. 2015. The insect peptide CopA3 increases colonic epithelial cell proliferation and mucosal barrier function to prevent inflammatory responses in the gut. J. Biol. Chem. 291: 3209-3223.
    Pubmed KoreaMed
  18. Nam ST, Kim DH, Lee MB, Nam HJ, Kang JK, Park MJ, et al. 2014. Insect peptide CopA3-induced protein degradation of p27Kip1 stimulates proliferation and protects neuronal cells from apoptosis. Biochem. Biophys. Res. Commun. 437: 35-40.
    Pubmed
  19. Nam HJ, Oh AR, Nam ST, Kang JK, Chang JS, Kim DH, et al. 2012. The insect peptide CopA3 inhibits lipopolysaccharide-induced macrophage activation. J. Pept. Sci. 18: 650-656.
    Pubmed
  20. Yoon IN, Hong J, Zhang P, Hwang JS, Kim H. 2013. An analog of the antimicrobial peptide CopA5 inhibits lipopolysaccharideinduced macrophage activation. J. Microbiol. Biotechnol. 27: 350356.
    Pubmed
  21. Chao X, Wang S, Zhao K, Li Y, Williams JA, Li T, et al. 2018. Impaired TFEB-mediated lysosome biogenesis and autophagy promote chronic ethanol-induced liver injury and steatosis in mice. Gastroenterology 155: 865-879 e812.
    Pubmed KoreaMed
  22. Chen MM, Palmer JL, Ippolito JA, Curtis BJ, Choudhry MA, Kovacs EJ. 2013. Intoxication by intraperitoneal injection or oral gavage equally potentiates postburn organ damage and inflammation. Mediators Inflamm. 2013: 971481.
    Pubmed KoreaMed
  23. Jamal M, Ameno K, Tanaka N, Ito A, Takakura A, Kumihashi M, et al. 2016. Ethanol and acetaldehyde after intraperitoneal administration to Aldh2-knockout mice-reflection in blood and brain levels. Neurochem. Res. 41: 1029-1034.
    Pubmed
  24. Kawaguchi S, Sakuraba H, Haga T, Matsumiya T, Seya K, Endo T, et al. 2019. Melanoma differentiation-associated gene 5 positively modulates TNF-α-induced CXCL10 expression in cultured HuH-7 and HLE cells. Inflammation 42: 2095-2104.
    Pubmed
  25. Sasaki Y, Asahiyama M, Tanaka T, Yamamoto S, Murakami K, Kamiya W, et al. 2020. Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content. Sci. Rep. 10: 7818.
    Pubmed KoreaMed
  26. Chen P, Hu M, Liu F, Yu H, Chen C. 2019. S-allyl-l-cysteine (SAC) protects hepatocytes from alcohol-induced apoptosis. FEBS. Open Bio 9: 1327-1336.
    Pubmed KoreaMed
  27. Verma VK, Li H, Wang R, Hirsova P, Mushref M, Liu Y, et al. 2016. Alcohol stimulates macrophage activation through caspasedependent hepatocyte derived release of CD40L containing extracellular vesicles. J. Hepatol. 64: 651-660.
    Pubmed KoreaMed
  28. Neuman MG, Maor Y, Nanau RM, Melzer E, Mell H, Opris M, et al. 2015. Alcoholic liver disease: Role of cytokines. Biomolecules 5:2023-2034.
    Pubmed KoreaMed
  29. Thakur V, Pritchard MT, McMullen MR, Nagy LE. 2006. Adiponectin normalizes LPS-stimulated TNF-α production by rat Kupffer cells after chronic ethanol feeding. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G998-1007.
    Pubmed KoreaMed
  30. Kawaratani H, Tsujimoto T, Douhara A, Takaya H, Moriya K, Namisaki T, et al. 2015. The effect of inflammatory cytokines in alcoholic liver disease. Mediators Inflamm. 2013: 495156.
    Pubmed KoreaMed
  31. Kawaratani H, Moriya K, Namisaki T, Uejima M, Kitade M, Takeda K, et al. 2017. Therapeutic strategies for alcoholic liver disease:Focusing on inflammation and fibrosis (Review). Int. J. Mol. Med. 40: 263-270.
    Pubmed
  32. Zhou Z, Sun X, Kang YJ. 2001. Ethanol-induced apoptosis in mouse liver: Fas- and cytochrome c-mediated caspase-3 activation pathway. Am. J. Pathol. 159: 329-338.
  33. Sakhuja, P. 2014. Pathology of alcoholic liver disease, can it be differentiated from nonalcoholic steatohepatitis? World J. Gastroenterol. 20: 16474-16479.
    Pubmed KoreaMed
  34. Celli R, Zhang X. 2014. Pathology of alcoholic liver disease. J. Clin. Transl. Hepatol. 2: 103-109.
  35. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. 2008. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J. Hepatol. 48: 821-828.
    Pubmed

Starts of Metrics

Share this article on :

  • mail

Related articles in MBL

Most KeyWord ?

What is Most Keyword?

  • It is most registrated keyword in articles at this journal during for 2 years.